Dicerna Pharmaceuticals Inc

NASDAQ:DRNA  
26.06
-0.36 (-1.36%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.96B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$46.52 Million
Adjusted EPS-$0.41
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

Dicerna Pharmaceuticals, Inc. Stock, NASDAQ:DRNA

33 Hayden Avenue, Lexington, Massachusetts 02421
United States of America
Phone: +1.617.621.8097
Number of Employees: 187

Description

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA.